If February 2, 2026, passed without triggering an action item on your regulatory calendar, it may be time to revisit your combination product quality strategy.
That’s the date FDA’s Quality Management System Regulation (QMSR) became effective, formally amending 21 CFR Part 820 and retiring the device Quality System Regulation (QSR) that had governed medical device manufacturing since 1996. For standalone device manufacturers, this transition has been widely discussed. For combination product sponsors, the implications are less straightforward and, in our experience, less well understood.
Here’s what you need to know.
What Changed: QSR Out, QMSR In
The QMSR doesn’t introduce entirely new quality concepts. It modernizes and harmonizes the existing framework. Its central feature is the incorporation by reference of ISO 13485:2016, the international standard for medical device quality management systems established by the International Organization for Standardization.
By aligning 21 CFR Part 820 with ISO 13485:2016, FDA’s goal is to harmonize the legal framework with the international standard for medical device QMS. Companies that have maintained ISO 13485 certification will find meaningful overlap, but the alignment is not one-to-one. Holding an ISO 13485 certificate does not automatically demonstrate QMSR compliance, and the structural and documentation differences deserve a careful gap assessment. FDA inspections assess compliance with QMSR, including FDA-specific provisions. FDA retained supplemental requirements to avoid inconsistencies with U.S. regulatory requirements.
Another significant change is the new FDA inspection program. FDA replaced QSIT with Compliance Program 7382.850. This is operationally important for device and combination product manufacturers because it changes not just inspection terminology, but how FDA investigators evaluate quality systems, what records they may review, and how firms should prepare for inspections. FDA implemented Compliance Program 7382.850 on February 2, 2026, concurrent with QMSR becoming effective.
In addition, under QMSR FDA may review management review records, internal audits, and supplier audit reports that were previously exempt from routine FDA review under the old regulation.
What This Means for Combination Product Sponsors
This is where combination product sponsors need to pay particular attention: the QMSR changes the device quality framework, but it does not change the CGMP compliance structure for combination products under 21 CFR Part 4.
FDA made conforming edits to Part 4 to align its references with the new QMSR terminology, but those edits do not alter the underlying CGMP requirements for combination products. Sponsors still operate under two compliance options for single entity and co-packaged combination products:
- Option 1 (Full Compliance): Comply with all CGMP requirements applicable to each constituent part — both drug CGMPs (21 CFR Parts 210/211) and the device QMSR (21 CFR Part 820).
- Option 2 (Streamlined Approach): Demonstrate compliance with either drug CGMPs or the device QMSR, plus specified provisions from the other framework.
Where previous guidance referenced “device QSR (21 CFR 820),” it now references the QMSR. If your regulatory strategy documentation, SOPs, inspection guides or quality agreements still reference QSR, they need updating, both for accuracy and to avoid confusion during FDA review or inspection.
Many organizations historically documented internal audit findings and management review discussions assuming they would not routinely be examined by FDA.
Now FDA may directly evaluate:
- Whether management reviews are meaningful
- Whether recurring quality issues are escalated
- Whether audit findings are appropriately investigated and closed
- Whether supplier oversight is effective
This significantly increases scrutiny of quality-system governance.
What Hasn’t Changed — and Why That Matters
It is equally important to understand what the QMSR does not affect for combination product sponsors:
- Biologics regulated under Section 351 of the PHS Act must still comply with 21 CFR Parts 600–680, regardless of which streamlined compliance path is chosen. A biologic constituent part is always subject to either drug CGMPs or the device QMSR in addition to applicable biologics regulations.
- HCT/P constituent parts must still comply with 21 CFR Part 1271, including current good tissue practice (CGTP) and donor eligibility requirements.
- Post-approval obligations, safety reporting under Part 4 Subpart B, and lead Center review structures are entirely unchanged.
FDA’s 2017 guidance on CGMP Requirements for Combination Products remains a primary reference for how FDA expects sponsors to implement the provisions of Part 4.
What You Should Do Now
If you haven’t already, conduct a targeted gap assessment. For combination product sponsors, focus on three areas:
- Update your regulatory documentation. References to “QSR” in CMC strategies, regulatory affairs plans, and quality agreements should be updated to QMSR throughout.
- Re-examine your streamlined approach justification. If you’re relying on Option 2 under Part 4 with a device-based operating system, confirm that your QMSR-aligned system captures all required drug CGMP provisions — and vice versa.
- Assess your device constituent part’s quality system. If a development partner or contract manufacturer is responsible for the device constituent, confirm their quality system has been updated to QMSR compliance and that the change is reflected in any quality or supply agreements.
- Update your inspection procedures to align with the new Compliance Program 7382.850.
The Bottom Line
The QMSR switchover is both simpler and more consequential than it appears. For pure device manufacturers, it is primarily a framework modernization. For combination product sponsors, it demands a deliberate review: the compliance structure under Part 4 hasn’t changed, but the regulatory language underpinning it has and that distinction matters when FDA reviewers or inspectors evaluate your dossier or quality system.
Getting ahead of this before a marketing application or inspection cycle is far less disruptive than addressing it under pressure.
Syner-G BioPharma Group provides comprehensive regulatory and CMC consulting for combination products across all development stages. For guidance on the QMSR transition or your combination product strategy, contact our team.
